Speaker Profile
M.D., Chair, Rutgers
Biography
Christian S. Hinrichs, M.D., serves as Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence (CIMCoE) and Chief of the Section of Cancer Immunotherapy. He also is Co-Leader of the Cancer Metabolism and Immunology Program. Dr. Hinrichs came to Rutgers Cancer Institute from the NCI where he held the position of tenured Senior Investigator and Lasker Clinical Research Scholar.
Dr. Hinrichs is a physician-scientist who has pioneered cell therapy for HPV-associated cancers and other epithelial cancers. He is known for the discovery of tumor-infiltrating lymphocyte therapy for the treatment of HPV-associated cancers, which was the first cell therapy to cause durable, complete responses in epithelial cancers. He also has discovered gene-engineered TCR-T cell therapies targeting HPV antigens and has demonstrated the safety and clinical activity of these treatments. His current laboratory research is focused on T cell receptor discovery, next-generation therapeutic approaches, and mechanisms of response to immunotherapy.
Dr. Hinrichs leads the cell therapy program at Rutgers Cancer Institute in conducting “bench-to-bedside and back again” research that leverages the specialized facilities of the cancer center to bring cutting-edge treatments to New Jersey patients. The specialized facilities of the program include the Cell Therapy Research Laboratory, Process Development Laboratory, and GMP Facility. Clinical trials with on-site GMP manufacturing include treatments for gastric cancer, non-small cell lung cancer, triple-negative breast cancer, cervical cancer, oropharyngeal cancer, anal cancer, and genital cancers.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: Erin Harris Cell & Gene
• David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
PMWC Award Ceremony
• Michel Sadelain, Columbia University
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
